Medindia LOGIN REGISTER
Medindia
Advertisement

Physicians Anticipate Higher Prescribing Based on JUPITER Study

Saturday, November 22, 2008 General News
Advertisement
SAN MATEO, Calif., Nov. 21 Just three days after theJUPITER trial results were presented at the American Heart Association meetingand simultaneously published online by the New England Journal of Medicine, anAlphaDetail survey of more than 100 primary care physicians shows thatphysicians anticipate a 14% increase in the use of drug therapy among theirhypercholesterolemia patients, particularly for low to moderate risk patients.
Advertisement

The JUPITER study showed that CRESTOR (rosuvastatin calcium) 20 mgsignificantly reduced major cardiovascular (CV) events by 44% compared withplacebo among men and women with elevated high-sensitivity C-reactive protein(hs-CRP) but low to normal low density lipoprotein cholesterol (LDL-C).
Advertisement

News about JUPITER spread quickly: Two-thirds of the physicians surveyedwere already aware of the study results within days of its release. Nearly 90%of the physicians surveyed report that they found the study results to bepositive, emphasizing how compelling they found the findings. However, somephysicians feel more data is needed and question if this benefit applies toall statins or is specific to CRESTOR.

Physicians report that they recognize the value of C-reactive protein.Two-fifths of physicians indicate that they strongly or very strongly agreethat hs-CRP plays an important role in cardiovascular disease. The mostintriguing part of the 2008 study lies in physicians future expectations.Following the JUPITER study results, physicians report that they anticipatemore than doubling the percent of patients for whom they test hs-CRP. Theincreased testing is likely to drive future prescribing behavior, particularlyfor patients with low to moderate risk factors.

Please contact Bob Latshaw at AlphaDetail for more information on theAlphaPulse study results or for additional insight regarding the market impactof the JUPITER study.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We area full-service primary market research firm, with a particular emphasis inlarge and complex quantitative studies for the global healthcare community.AlphaDetail is built on one of the industry's strongest foundations thatincludes a large team of exceptional analytical specialists, the industry'sleading technology platform and a flexible approach to research that helps usto answer our clients' most challenging questions.

SOURCE AlphaDetail, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close